AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14671905 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and intravenous bolus injections of fentanyl with epidural anesthesia by morphine at lumbar level
Number of subjects: 82
Study 10735887 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg/d
Number of subjects: 769
Study 10735887 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 40 mg four times daily
Number of subjects: 769
Study 9367070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral retinol (25,000 units)
Number of subjects: 525
Study 9367070 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (5-10 mg)
Number of subjects: 525
Study 9367070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 1396624 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam-flumazenil
Number of subjects: 80
Study 1396624 — intervention group
Group type: COMPARATOR
Intervention: propofol
Number of subjects: 80
Study 3891264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 77
Study 3891264 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 77
Study 31584684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for MRSA bacteremia
Number of subjects: 73
Study 31584684 — intervention group
Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for MRSA bacteremia
Number of subjects: 73
Study 31584684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for CAUTI
Number of subjects: 73
Study 31584684 — intervention group
Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for CAUTI
Number of subjects: 73
Study 31584684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for CLABSI
Number of subjects: 73
Study 31584684 — intervention group
Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for CLABSI
Number of subjects: 73
Study 31584684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (30% decrease in daily rates) for CDI
Number of subjects: 73
Study 31584684 — intervention group
Group type: COMPARATOR
Intervention: Control group (30% decrease in daily rates) for CDI
Number of subjects: 73
Study 31584684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group for MRSA acquisition
Number of subjects: 73
Study 31584684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group for VRE acquisition
Number of subjects: 73
Study 31584684 — intervention group
Group type: COMPARATOR
Intervention: Control group for MRSA acquisition
Number of subjects: 73
Study 31584684 — intervention group
Group type: COMPARATOR
Intervention: Control group for VRE acquisition
Number of subjects: 73
Study 29972861 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 212
Study 29972861 — intervention group
Group type: EXPERIMENTAL
Intervention: No fentanyl
Number of subjects: 212
Study 29972861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl and No fentanyl
Number of subjects: 212
Study 27428192 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 134
Study 27428192 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 134
Study 25416557 — intervention group
Group type: EXPERIMENTAL
Intervention: Six sessions of basic counseling over a period of 3 to 4 months provided by trained community health workers (CHWs)
Number of subjects: 420
Study 25416557 — intervention group
Group type: COMPARATOR
Intervention: Three monthly phone calls from a CHW trained to conduct phone calls but not basic counseling
Number of subjects: 420
Study 22136660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) administered to mothers during late pregnancy
Number of subjects: 98
Study 22136660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 20653331 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2148
Study 20653331 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (titrated to heart rate)
Number of subjects: 2148
Study 17355936 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (L-Arg) therapy
Number of subjects: 68
Study 17355936 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 68
Study 15705120 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR 150 mg
Number of subjects: 60
Study 15705120 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR 75 mg
Number of subjects: 60
Study 15705120 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 12011124 — intervention group
Group type: COMPARATOR
Intervention: ACVBP chemotherapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Number of subjects: 370
Study 12011124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem-cell transplantation (ASCT)
Number of subjects: 370
Study 12011124 — intervention group
Group type: COMPARATOR
Intervention: ACVBP chemotherapy
Number of subjects: 370
Study 12011124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 370
Study 9623011 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 15
Study 9623011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7672654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate, administered pre-operatively for three months
Number of subjects: 28
Study 7672654 — intervention group
Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 28
Study 2240053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lysine vasopressin (LV)
Number of subjects: 6
Study 2240053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 269932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg
Number of subjects: 37
Study 269932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 650 mg
Number of subjects: 37
Study 269932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 200 mg
Number of subjects: 37
Study 269932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg
Number of subjects: 37
Study 269932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 269932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 37
Study 269932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 37
Study 31608821 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin ideal images (for females)
Number of subjects: 200
Study 31608821 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular ideal images (for males)
Number of subjects: 200
Study 31608821 — intervention group
Group type: COMPARATOR
Intervention: Control group (images of houses)
Number of subjects: 200
Study 31608821 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress (K10 scale)
Number of subjects: 200
Study 31553834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg infusion on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46)
Number of subjects: 769
Study 31553834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg infusion)
Number of subjects: 769
Study 31553834 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg subcutaneous injection at week 1, 80 mg at week 2, and 40 mg every 2 weeks thereafter)
Number of subjects: 769
Study 31553834 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg subcutaneous injection)
Number of subjects: 769
Study 31553834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 769
Study 31553834 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 769
Study 28915826 — intervention group
Group type: EXPERIMENTAL
Intervention: HuoXueSanFeng acupuncture combined with one antihypertensive medication
Number of subjects: 480
Study 28915826 — intervention group
Group type: COMPARATOR
Intervention: One antihypertensive medication and basic treatments for ischemic stroke
Number of subjects: 480
Study 26086941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26086941 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU cholecalciferol
Number of subjects: 30
Study 26086941 — intervention group
Group type: EXPERIMENTAL
Intervention: 400,000 IU cholecalciferol
Number of subjects: 30
Study 24633278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear nail polish
Number of subjects: 50
Study 24633278 — intervention group
Group type: EXPERIMENTAL
Intervention: Red nail polish
Number of subjects: 50
Study 24633278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic nails
Number of subjects: 50
Study 24633278 — intervention group
Group type: EXPERIMENTAL
Intervention: Black nail polish
Number of subjects: 50
Study 24633278 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown nail polish
Number of subjects: 50
Study 21880326 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-therapy (direct treatment)
Number of subjects: 42
Study 21880326 — intervention group
Group type: COMPARATOR
Intervention: Vocal-hygiene program (indirect treatment)
Number of subjects: 42
Study 19744323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside chair and bed pressure sensors with radio-paging alerting mode
Number of subjects: 0
Study 19744323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without the use of sensors)
Number of subjects: 0
Study 17902520 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision with midline closure (EMC group)
Number of subjects: 380
Study 17902520 — intervention group
Group type: COMPARATOR
Intervention: Excision without closure (EWC group)
Number of subjects: 380
Study 14630836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with reaming
Number of subjects: 224
Study 14630836 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing without reaming
Number of subjects: 224
Study 11141029 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical infant orthopedic treatment (PIO) during the first year of life
Number of subjects: 20
Study 11141029 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (no PIO)
Number of subjects: 20
Study 11141029 — intervention group
Group type: COMPARATOR
Intervention: Children with cleft lip and palate
Number of subjects: 20
Study 9350557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and water
Number of subjects: 0
Study 9350557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and toothpaste slurry
Number of subjects: 0
Study 9350557 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste slurry and water
Number of subjects: 0
Study 9350557 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 0
Study 8459971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium etidronate 400 mg/day for 14 days followed by calcium carbonate 500 mg/day for 42 days plus norethindrone 2.5 mg/day
Number of subjects: 11
Study 8459971 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone 10 mg/day
Number of subjects: 11
Study 8459971 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist only (Group III)
Number of subjects: 11
Study 8459971 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group IV)
Number of subjects: 11
Study 3533677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg each morning for one day before reaching 3000m
Number of subjects: 48
Study 3533677 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Caucasian subjects and lowland and highland Africans)
Number of subjects: 48
Study 30873549 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 61
Study 30873549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30225268 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a nurse‐led diabetes self‐management education for 12 weeks
Number of subjects: 142
Study 30225268 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 142
Study 26795100 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (HD)
Number of subjects: 0
Study 24584065 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording patient's estimated 3-month functional prognosis
Number of subjects: 630
Study 24584065 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient wanted life support regardless of functional outcome
Number of subjects: 630
Study 24584065 — intervention group
Group type: COMPARATOR
Intervention: Control group (patient did not want continued life support without a reasonable chance of independent living)
Number of subjects: 630
Study 22538118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2 g ginger powder in hot water)
Number of subjects: 10
Study 22538118 — intervention group
Group type: COMPARATOR
Intervention: Control (no ginger)
Number of subjects: 10
Study 19539141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stenting (SES)
Number of subjects: 130
Study 19539141 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB) surgery
Number of subjects: 130
Study 17611204 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening
Number of subjects: 408
Study 17611204 — intervention group
Group type: COMPARATOR
Intervention: Control (no preimplantation genetic screening)
Number of subjects: 408
Study 14993866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean beef
Number of subjects: 86
Study 14993866 — intervention group
Group type: COMPARATOR
Intervention: Lean poultry and fish
Number of subjects: 86
Study 14993866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 12638335 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive workload training (Group A)
Number of subjects: 16
Study 12638335 — intervention group
Group type: COMPARATOR
Intervention: Not trained (Group B)
Number of subjects: 16
Study 10453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bupropion
Number of subjects: 457
Study 10453796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 10453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label bupropion
Number of subjects: 457
Study 10453796 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-prevention phase (bupropion)
Number of subjects: 457
Study 7775988 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-related activities
Number of subjects: 4920
Study 7775988 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient care activities
Number of subjects: 4920
Study 7775988 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal time
Number of subjects: 4920
Study 7775988 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent in transit
Number of subjects: 4920
Study 2104627 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II infusion
Number of subjects: 83
Study 2104627 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-III infusion
Number of subjects: 83
Study 2104627 — intervention group
Group type: COMPARATOR
Intervention: Captopril (ACE inhibitor)
Number of subjects: 83
Study 2104627 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor) for 30 days
Number of subjects: 83
Study 211983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate high-dose (1 ml) with family therapy
Number of subjects: 104
Study 211983 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine enanthate low-dose (0.25 ml) with no therapy
Number of subjects: 104
Study 211983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine enanthate low-dose (0.25 ml) with family therapy
Number of subjects: 104
Study 31277886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training program in 10 sessions for 45 min
Number of subjects: 24
Study 31277886 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not participate in the cognitive rehabilitation program)
Number of subjects: 24
Study 28797624 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30
Study 28797624 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 26071592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 75
Study 26071592 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 75
Study 23343682 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 113
Study 23343682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 21107542 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude residents
Number of subjects: 28
Study 21107542 — intervention group
Group type: COMPARATOR
Intervention: Sea level residents
Number of subjects: 28
Study 19223643 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899 50 mg capsule
Number of subjects: 0
Study 19223643 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899 200 mg capsule
Number of subjects: 0
Study 19223643 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899 800 mg once daily (QD)
Number of subjects: 0
Study 19223643 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899 400 mg twice daily (BID)
Number of subjects: 0
Study 19223643 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899 under fed conditions
Number of subjects: 0
Study 19223643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17357181 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week controlled antidepressant monotherapy trial
Number of subjects: 42
Study 16036027 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 16036027 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release metoprolol
Number of subjects: 0
Study 11345160 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dilator (Breathe Right, 3M)
Number of subjects: 18
Study 11345160 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dilator (Breathe Right, 3M) in subgroup of habitual snorers (n = 6)
Number of subjects: 18
Study 11345160 — intervention group
Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 18
Study 9325593 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who were outperformed by a confederate on a perceptual intelligence test
Number of subjects: 0
Study 9325593 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who outperformed confederates on a perceptual intelligence test
Number of subjects: 0
Study 7950110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal tunneling
Number of subjects: 54
Study 7950110 — intervention group
Group type: COMPARATOR
Intervention: Corneoscleral tunneling (Control)
Number of subjects: 54
Study 6476557 — intervention group
Group type: EXPERIMENTAL
Intervention: New cardiopulmonary-cerebral resuscitation therapies
Number of subjects: 0
Study 31409338 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS generating alerts based on clinically relevant pDDIs
Number of subjects: 9
Study 29265923 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally matched D‐PSAs
Number of subjects: 567
Study 29265923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatched D‐PSAs (particularly refutational)
Number of subjects: 567
Study 29265923 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately matched messages
Number of subjects: 567
Study 29265923 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐sided moderately matched messages
Number of subjects: 567
Study 29265923 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 567
Study 27938637 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education program delivered by peer educators
Number of subjects: 0
Study 24588932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (6 different probiotic strains; 10^9 cfu/g) for 6 weeks
Number of subjects: 40
Study 24588932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g sachet per day for 6 weeks)
Number of subjects: 40
Study 24588932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 40
Study 24588932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23214314 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 210
Study 23214314 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray combined with Hydrochloric acid left Kabbah Sting nasal spray
Number of subjects: 210
Study 23214314 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education management and lifestyle intervention (on the basis of group B's therapy)
Number of subjects: 210
Study 23214314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 210
Study 20713677 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir-ritonavir mono- or tritherapy
Number of subjects: 45
Study 18162699 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI study of covert verb generation (VG) in children with TBI
Number of subjects: 8
Study 18162699 — intervention group
Group type: COMPARATOR
Intervention: fMRI study of covert verb generation (VG) in children with orthopedic injuries (OI)
Number of subjects: 8
Study 18162699 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD signal activation
Number of subjects: 8
Study 18162699 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MR images
Number of subjects: 8
Study 16885042 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 400 mg/d
Number of subjects: 52
Study 16885042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15234671 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 0
Study 11020745 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 4 microg/kg
Number of subjects: 120
Study 11020745 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine test dose
Number of subjects: 120